Immuneel and THSTI Partner to Advance CAR-T Cell Therapy and Lentiviral Vector Manufacturing in India
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
Cancer Cell Therapy Trials Show Progress
Table of ContentsCancer Cell Therapy Pipeline AdvancesCHM CDH17 Targets Gastrointestinal CancersCancer Cell Therapy Shows Tumor ShrinkageCancer Cell Therapy Safety Signals StrengthenChimeric Therapeutics Prepares for MilestonesCancer Cell Therapy Outlook Remains Promising Cancer cell therapy developer Chimeric Therapeutics is reporting encouraging progress across its clinical-stage oncology portfolio. The company’s latest updates highlight early…
Until a few years ago, the treatment known as CAR-T was only available in some of the most advanced medical centers in the world. Today it is also applied in Uruguay. This innovative immunotherapy represents a new hope for patients with certain types of leukemias and lymphomas that no longer respond to conventional treatments.The technique was incorporated into the country by the Pérez Scremini Foundation, after years of research and internation…
Immuneel and THSTI Partner to Advance CAR-T Cell Therapy and Lentiviral Vector Manufacturing in India
Immuneel Therapeutics and THSTI Announce Strategic Partnership to Advance CAR-T Cell Therapy and Lentiviral Vector Manufacturing Bengaluru & Faridabad – 27 July, 2026: Immuneel Therapeutics Private Limited and the BRIC-Translational Health Science and Technology Institute (THSTI) have officially entered into a Memorandum of Understanding (MoU), to establish a collaboration to qualify, establish, and manage a […] The post Immuneel and THSTI Partn…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
